Advancing Precision Immunology in Vitiligo: Positioning CXCL10 Therapies to Move Beyond Symptom Management
- Evaluating CXCL10 in vitiligo, targeting tissue-resident memory T cells driving depigmentation, to advance more durable and disease-modifying approaches beyond current standard-of-care therapies
- Assessing how CXCL10 compares with JAK inhibitors and phototherapy approaches, addressing limitations around chronic use, safety and relapse, to differentiate next generation vitiligo pipelines in an underserved market
- Understanding growing investor confidence in dermatology innovation, accelerating development in high-unmet-need autoimmune skin disease, to strengthen the commercial outlook for emerging vitiligo therapeutics